EZH1 and acute myeloid leukemia: Importantly, patients with a higher level of EZH1 showed a worse overall survival (OS, median = 23.0 vs. 46.0 months, P = 0.016) and event-free survival (EFS, median = 15.1 vs. 28.0 months, P = 0.010) than those with lower EZH1 expression (Fig. 1f and Supplementary Table 3 of Univariate and multivariate analyses for OS and EFS in 62 AML patients).